Month: July 2014 (page 2 of 4)

truvia is toxic to fruit flies

Dead fruit fly. Picture from wikipedia

C&EN describes how a sixth grade science project lead to the discovery that Truvia, a sweetner from the stevia plant, is toxic to fruit flies:

The discovery wouldn’t have been possible without Simon D. Kaschock-Marenda, who went to his dad three years ago to pitch an idea. Knowing that his father was a neurobiologist at Drexel with access to a supply of fruit flies, the sixth-grader proposed a science fair project: He wanted to feed a variety of sugars and sweeteners to flies and see how the insects fared.

One of the sweeteners father and son purchased from the supermarket for testing was Truvia, made by Minneapolis-basedCargill. The pair mixed that sweetener and a number of others with Drosophila food, put each in a container with adult fruit flies, and waited.

Almost a week later, Marenda’s son pointed out that the flies in the Truvia container had died, while the ones feeding off the other sweeteners were still alive. Thinking the result might be a fluke, the youngster and his father repeated the experiment, only to obtain the same result. Flies raised on the Truvia-laced food survived for about six days, and flies fed table sugar lived around 40 to 50 days.

The research was moved into the father’s lab where he discovered that erythritol is responsible for toxicity:

[F]ruit flies given food laced with Pure Via, another sweetener derived from the stevia plant, didn’t react as they had to Truvia. Their life span was unaltered.

So O’Donnell sent Truvia off to be analyzed with high-performance liquid chromatography and got interesting results. “More than 90% of the Truvia was erythritol,” Marenda says.

[…]

To determine whether erythritol was indeed their culprit, Marenda, O’Donnell, and their team placed fruit flies in containers with increasing doses of erythritol. At the highest concentration the researchers tested—2 M erythritol—all the flies died after a day or two of feeding.

child actually not HIV free

HIV medications

A child thought to be cured of HIV is actually still infected. The child received aggressive treatment immediately after birth, which made the virus undetectable. Now the child is showing signs of viral infection again, after two years without therapy. From the Bloomberg:

The child, born to an HIV-infected mother, is now nearly four years old. It was found to have detectable HIV levels in its blood during a routine clinical care visit earlier this month, according to a statement by the National Institute of Allergy and Infectious Diseases.

Doctors had unintentionally stopped giving anti-retroviral treatments to the child at 18 months. When care resumed five months later, medical staff couldn’t detect the virus and the speculation was that the child was free of the illness.

“Obviously, as an individual patient it’s disappointing,” said Anthony Fauci, director of NIAID, in a telephone interview. “But we’re learning very important things. Our capability of detection isn’t good enough. This reservoir is extraordinary, and we need to get better tools to measure it accurately.”

drug delivery via red blood cells

A group of researchers have developed a method for attaching drugs to the surfaces of red blood cells. RBC precursor cells are engineered to express a surface protein (purple oval) with a sortase substrate sequence. When the precursor cells become RBCs, sortase is added to form an RBC-enzyme intermediate. A modified drug can then react with the intermediate to form an RBC-drug conjugate. Picture from cen.acs.org

In this week’s CEN, Stu Borman describes a new drug delivery strategy. Researchers at The Whitehead Institute have developed a method for conjugating drugs to red blood cell surfaces increase drug longevity and bioavailability:

 Hidde L. PloeghHarvey F. Lodish, and coworkers at MIT’s Whitehead Institute for Biomedical Research have created RBC-drug conjugates that could take drug longevity to another level (Proc. Natl. Acad. Sci. USA 2014, DOI: 10.1073/pnas.1409861111). They’ve shown longevities of 28 days in mice but hope for more in people, where RBCs live up to four months.

They engineer mouse or human RBC precursor cells to express a surface protein bearing a sequence recognized by the enzyme sortase. Once the cells develop into RBCs, they add sortase, forming a covalent RBC-enzyme intermediate. A modified drug can then react with the intermediate, expelling sortase and yielding an RBC-drug conjugate. Sortase-based cell-surface labeling is an established technique, but this is the first time it’s been used for diagnostic or therapeutic purposes.

//naugaglaucoothu.net/4/4535925